Request for Proposals: Cellular Screening Assay Development for DYT1 Dystonia
The goal of this RFP is to develop a human cellular assay for torsinA function/DYT1 dysfunction that can be automated and used for RNAi screening to complete the project described below. Funding will be provided to develop or transform assay protocols that can be adopted for high throughput molecular screening. Read-outs can be plate reader-based or high content-based.
In a collaborative program with the Dystonia Medical Research Foundation (DMRF), BioFocus, a Galapagos subsidiary, screened its SilenceSelect™ adenoviral shRNA collection in a cell-based high throughput assay to identify proteins that, upon RNAi knockdown, can restore aberrant protein secretion in a cellular model of DYT1 dystonia and thereby identify potential drug targets. In this assay, protein secretion was measured using secreted alkaline phosphatase (SEAP), which was affected by knock-down of TOR1A (torsinA), the gene causing DYT1 dystonia. The human neuroblastoma SH-SY5Y cell line was used for the assay and subsequently optimized for high throughput screening and automation. The complete BioFocus SilenceSelect™ collection was screened and, ultimately, 355 non-toxic shRNA hits were identified. These hits must now be further validated in orthogonal cell-based assays of torsinA function or dysfunction. Such validated targets would then form the basis of a drug discovery program.
Conditions of Award
Any individual with appropriate scientific credentials employed by a non-profit or for-profit institution, domestic or foreign is eligible to apply. A letter of intent is required and should be submitted electronically to DMRF by March 15, 2013. The application receipt date is April 15, 2013. Additional scientific details about the project will be sent to all applicants whose letters of intent are approved.
It is anticipated that one contract award will be made. The terms and conditions, including the dollar amount of the contract will be negotiated with the recipient. It is expected that the recipient will actively collaborate with the BioFocus and DMRF staff in successful development and implementation of the assay.
Address for Inquiries and Submissions
Jody Roosevelt at email@example.com or 312-447-5150 begin_of_the_skype_highlighting 312-447-5150 FREE end_of_the_skype_highlighting